In support of the Endometriosis Foundation of AmericaSince 2017 · 10 years in 2027
EndoNews
MenuClose

Clinical Trial Tested Safety of Potential New Drug to Manage Endometriosis

Clinical Trial Tested Safety of Potential New Drug to Manage Endometriosis

The drug candidate of a non-peptide gonadotropin-releasing hormone (GnRH) antagonist had a good safety profile in clinical trial.

Key Points

Highlights: 

  • The safety, pharmacokinetics, and pharmacodynamics of SHR7280, a non-peptide gonadotropin-releasing hormone antagonist, are favorable in a phase 1 clinical trial.

Importance:

  • SHR7280 could be further developed as a potential drug to manage endometriosis symptoms.

What’s done here:

  • Researchers conducted a phase 1 clinical trial in 30 premenopausal women with endometriosis using 3 different doses of SHR7280 to test the safety, pharmacokinetics, and pharmacodynamics of the drug. 

Key results:

  • The treatment was well-tolerated.
  • Seventy-nine% of women receiving the drug and 83% of those receiving placebo reported adverse events,  there were no severe adverse events.
  • SHR7280 was rapidly absorbed and the plasma concentration was dose-dependent.
  • SHR7280 could effectively suppress both estradiol and luteinizing hormone and prevent progesterone increase in a dose-dependent manner. 

Lay Summary

The non-peptide gonadotropin-releasing hormone antagonist SHR7280 has favorable safety, pharmacokinetics, and pharmacodynamics in 3 different doses, according to the results of a phase 1 clinical trial published in the scientific journal Clinical Pharmacokinetics.

“The results of this study provide evidence to support the further development of SHR7280 as a gonadotropin-releasing hormone antagonist for the treatment of endometriosis-related pain in the subsequent Phase 2 trial,” wrote the authors of the study.

In the phase 1 portion of the trial, 24 premenopausal women received SHR7280 while 6 received a placebo for 21 consecutive days. The treatment dose started from 200 mg daily and then increased to 300 mg daily and 200 mg twice a day, and the results showed that the drug was well tolerated. 

A total of 79% of the patients and 83% of those who received the placebo reported adverse events, most of these were mild. 

The mean half-life at steady state was 6.9 hours for the 200 mg-a-day dose, 7.4 hours for the 300 mg-a-day dose, and 2.8 hours for the 200 mg twice-a-day dose. There was little or no accumulation observed. 

Pharmacodynamic analysis showed that the drug could effectively suppress the concentration of estradiol and luteinizing hormone and prevent progesterone increase in a dose-dependent manner within the desired therapeutic window, throughout the treatment period.

Research source: https://pubmed.ncbi.nlm.nih.gov/37838623/

PubMed: 37838623

DISCLAIMER

EndoNews highlights the latest peer-reviewed scientific research and medical literature that focuses on endometriosis. We are unbiased in our summaries of recently-published endometriosis research. EndoNews does not provide medical advice or opinions on the best form of treatment. We highly stress the importance of not using EndoNews as a substitute for seeking an experienced physician.

Necessary cookies support secure sign-in and account features.

Strictly necessaryAlways active
Analytics cookiesOff

Google Analytics receives limited, cookieless visit measurements by default. With your permission, analytics cookies help us understand visits over time. Advertising features stay disabled. You can change your choice here at any time. Embedded media may connect to its provider when displayed.

Privacy policy

A clearer view of
endometriosis research.